Grant Sean's Form 4/A amendment
AmendedVera Therapeutics, Inc. (VERA) · filed Feb 17, 2023
- Accession no.
- 0001209191-23-010583
- Filed
- Feb 17, 2023
- Trade date
- Feb 6, 2023
- Filing delay
- 11 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Feb 8, 2023
This filing lists 1 non-derivative transaction. Open-market purchases total $100.0K. It was filed 11 days after the trade.
This amendment replaces 0001209191-23-007769 (filed Feb 8, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Grant SeanCIK 0001872792 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2023 | Class A Common Stock | PPurchaseAcquired | +14,285 | $7.00 | +$99,995 | 49,933 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reporting person's original Form 4 contained a typographical error on the transaction date.
- F2
Shares purchased by the Reporting Person in the Issuer's follow-on offering, which closed on February 6, 2023. The purchase price is the offering price.
- F3
Includes 380 shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022.